Abstract:Since the approval of the first checkpoint inhibitor, ipilimumab (α-CTLA4), there continues to be enthusiasm around leveraging the immune system to eradicate solid tumors. However, unknowns about the cellular mechanism(s) that cause some patients to durably respond while others relapse, continue to stymie the field. To support ongoing efforts elucidating cell subsets responsible for differences in patient responses, we aim to evaluate the functional heterogeneity of T-cell subsets responding to checkpoint inhibitors in mouse models of solid tumors. Single-cell RNA-seq has enabled discoveries of transcriptionally defined cell subsets, but understanding their function require inference from transcription, flow-based validation biased by pre-selection of subsets with specific markers, or reliance on surrogate markers for cell-extrinsic functions (e.g., cytotoxicity). Thus, functional heterogeneity could be obscured. To address this, we leveraged a novel technology that converges live, cellular functions with transcriptomics at the resolution of single cell-cell interactions. This technology captures tens of thousands of individual cells or defined combinations of groups of cells in bio-compatible hydrogel compartments, enabling longitudinal imaging over days to weeks. Throughout this period, functions are characterized via bright-field or immunofluorescence readouts, including antibodies, cytokine capture beads, and dyes. Cells are then lysed within compartments to generate barcoded libraries for mRNA-sequencing and gene signatures from individual cells computationally deconvoluted. With this technology, we developed a novel assay that enables longitudinal, unbiased functional characterization of individual T cells mapped to single-cell transcriptomics. Single mouse primary T cells were encapsulated with one or more MC38 target cells and imaged over time. We validated combinations of different readouts can be measured from the same T-cell, including cell-counts for proliferation, CD8/3 expression to differentiate T cells from target cells, activation markers, and / or target cell death via Sytox. Thus, single T cells can be multi-functionally evaluated over time, enabling the study of attributes inaccessible at high scale with prior technologies, including kinetics of killing or the number of target cells killed by a single T-cell. For assays combining cytotoxicity and surface receptors, we generated barcoded libraries from functionally characterized T cells for sequencing and developed an analytical pipeline that deconvolutes mRNA from single T cells mapped to their multi-functional profiles, to identify novel pathways that regulate anti-tumor functions. We will leverage this workflow to functionally characterize single T cells in tumor-bearing mice treated with checkpoint inhibitors and map the data to underlying transcriptomics. In doing so, we aim to discover functional subsets, potentially with identical transcriptional profiles, to support hypothesis generation around mechanisms governing anti-tumor efficacy of checkpoint inhibitors. Citation Format: Jacqueline Yee, Praveer Sharma, Yunmin Li, Isaac Thomas, Pier F Gherardini, Teresa Ai, Mostafa Ronaghi, Gary Schroth, Matthew H Spitzer. Novel workflow for characterizing T-cell functional heterogeneity in response to checkpoint inhibitors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A025.

Abstract 6633: Tracking cell-cell interactions using intercellular barcode transfer

Abstract LB289: Single-cell CRISPR screens at scale to understand T cell biology

Abstract 2944: A high-throughput screening system for identifying therapeutic targets in immuno-oncology

Cellular behavior analysis from live-cell imaging of TCR T cell-cancer cell interactions

Abstract B037: ClonMapper Duo: An scRNAseq compatible lineage tracing method to track cell-cell fusion at single-cell resolution

Abstract 6202: Integrating public single-cell transcriptomics and patient profiles to guide clinical development

Abstract A025: Novel workflow for characterizing T-cell functional heterogeneity in response to checkpoint inhibitors

Abstract 7042: Enhancing TCR T cell function in solid tumors through in vivo combinatorial screens and single-cell analysis

Cellular barcoding: From developmental tracing to anti-tumor drug discovery

Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses

Abstract 3092: MICRO-TAG: A novel fluorescence-based real-time cellular target engagement platform for drug discovery

Abstract A136: Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles

Abstract IA002: Inference of intercellular signaling activities in tumor spatial and single-cell transcriptomics, with applications in identifying cancer immunotherapy targets

Abstract 4280: Automatic identification of cancer cell-cell interfaces at the pixel level

Abstract 5552: Uncovering clinically significant tumor microenvironment interaction programs across diverse cancers

Abstract 2840: Identification of a safe harbor CRISPR-Cas9 integration site for improved cell therapy safety and potency

Abstract 270: Cell assay on a chip to study tumor initiating cells’ heterogeneity and treatment resistance.

Abstract 8: Deep Immunomics pipeline for discovery and validation of novel cancer-specific T cell receptors

Abstract 1689: CRISPR functional genetic screening for immune enhancers of inhibitor receptors in human primary CD8 T cells

Abstract 5637: Path to the holy grail of spatial biology: Spatial single-cell whole transcriptomes using 6000-plex spatial molecular imaging on FFPE tissue

Abstract 2949: A flexible and efficient approach for single-cell CRISPR perturbation screens combined with targeted RNA-seq expression analysis